Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 5/20 | 0.68 |
| ▸ | BCHE | P06276 | 7/20 | 0.66 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.64 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.64 |
| ▸ | SOD1 | P00441 | 1/20 | 0.58 |
| ▸ | MAOA | P21397 | 1/20 | 0.57 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.57 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.56 |
| ▸ | LCK | P06239 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29925214 | 1.00 | MAOB (0.68) | MAOBBCHECYP4F2CYP4A11SOD1 | |
| Methylamine SCHEMBL9454395 | 0.96 | MAOB (0.64) | MAOBBCHECYP4F2CYP4A11SOD1 | |
| Formaldehyde SCHEMBL27752554 | 0.95 | MAOB (0.62) | MAOBBCHECYP4F2CYP4A11SOD1 | |
| SCHEMBL13462828 | 0.92 | MAOB (0.58) | MAOBBCHECYP4F2CYP4A11SOD1 | |
| SCHEMBL3918721 | 0.89 | MAOB (0.58) | MAOBBCHECYP4F2CYP4A11SOD1 | |
| Acetic Acid Methyl Ester SCHEMBL28085683 | 0.87 | MAOB (0.62) | MAOBBCHECYP4F2CYP4A11NR4A2 | |
| SCHEMBL13753986 | 0.86 | MAOB (0.59) | MAOBBCHECYP4F2CYP4A11MAOA | |
| SCHEMBL13463060 | 0.86 | SMN1; SMN2 (0.57) | MAOBBCHECYP4F2CYP4A11SOD1 | |
| SCHEMBL13462938 | 0.86 | MAOB (0.65) | MAOBBCHERAB9A | |
| SCHEMBL13462917 | 0.86 | MAOB (0.60) | MAOBBCHECYP4F2CYP4A11SOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 195 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025235719-A1 | DIMERIC SMAC MIMETICS USEFUL IN HIV THERAPY | VIIV HEALTHCARE COMPANY (US) | 2025-11-13 | — | — | WO | disclosed |
| WO-2025217560-A1 | TRIAZOLO INDAZOLE COMPOUNDS AS JAK INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2025-10-16 | — | — | WO | disclosed |
| US-12398135-B2 | Dimethyl amino azetidine amides as JAK inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2025-08-26 | — | — | US | disclosed |
| US-20250034131-A1 | DIMETHYL AMINO AZETIDINE AMIDES AS JAK INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2025-01-30 | — | — | US | disclosed |
| EP-4114836-B1 | CRYSTALLINE HYDRATE OF A JAK INHIBITOR COMPOUND | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2025-01-08 | — | — | EP | disclosed |
| US-12122773-B2 | Crystalline hydrate of a JAK inhibitor compound | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2024-10-22 | — | — | US | disclosed |
| EP-3837258-B1 | DIMETHYL AMINO AZETIDINE AMIDES AS JAK INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2024-04-24 | — | — | EP | disclosed |
| US-20240025897-A1 | CRYSTALLINE HYDRATE OF A JAK INHIBITOR COMPOUND | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2024-01-25 | — | — | US | disclosed |
| WO-2023205701-A1 | MACROCYCLIC HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| CN-112703037-B | 5-to 7-membered heterocyclic amides as JAK inhibitors | 施万生物制药研发IP有限责任公司 | 2023-10-20 | — | — | CN | disclosed |
| US-5840684-A | Glycopeptide antibiotic derivatives | ELI LILLY AND COMPANY (US) | 1998-11-24 | — | — | US | disclosed |
| EP-0460679-B1 | Endothelin antagonistic peptide derivatives | BANYU PHARMA CO LTD (JP) | 1998-10-28 | — | — | EP | disclosed |
| EP-0617022-B1 | 6,7, dialkoxy-3,4-dihydroisoquinolin-8-ol, process for preparation thereof and process for preparation of 6,7-dialkoxy-1,2,3,4-tetrahydroisoquinolin-8-ol using the compound | BANYU PHARMA CO LTD (JP) | 1998-02-11 | — | — | EP | disclosed |
| US-5691315-A | CARDIOVASCULAR DISORDERS; VASODILATOR; BRONCHODILATOR | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1997-11-25 | — | — | US | disclosed |
| US-5498717-A | CHEMICAL INTERMEDIATES FOR PRODUCING ANTITUMOR POTENTIATORS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1996-03-12 | — | — | US | disclosed |
| US-5470833-A | Vasodilators, bronchodilators | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1995-11-28 | — | — | US | disclosed |
| US-5446164-A | Regioselective cyclization of phenethylamide derivative in presence of phosphoric acid halide, reducing formed compound | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1995-08-29 | — | — | US | disclosed |
| US-5444152-A | Vasolidator or bronchodilator | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1995-08-22 | — | — | US | disclosed |
| EP-0617022-A1 | 6,7, dialkoxy-3,4-dihydroisoquinolin-8-ol, process for preparation thereof and process for preparation of 6,7-dialkoxy-1,2,3,4-tetrahydroisoquinolin-8-ol using the compound | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1994-09-28 | — | — | EP | disclosed |
| EP-0460679-A2 | Endothelin antagonistic peptide derivatives | Banyu Pharmaceutical Co., Ltd. (JP) | 1991-12-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250034131-A1 | DIMETHYL AMINO AZETIDINE AMIDES AS JAK INHIBITORS | JAK1, JAK2, JAK3 | MAOB 2057/4885BCHE 4048/4885CYP4F2 3294/4885 |
| US-12398135-B2 | Dimethyl amino azetidine amides as JAK inhibitors | JAK1, JAK2, JAK3 | MAOB 2057/4885BCHE 4048/4885CYP4F2 3294/4885 |
| US-12122773-B2 | Crystalline hydrate of a JAK inhibitor compound | JAK1, JAK2, JAK3 | MAOB 4094/4885BCHE 4788/4885CYP4F2 1421/4885 |
| US-20240025897-A1 | CRYSTALLINE HYDRATE OF A JAK INHIBITOR COMPOUND | JAK1, JAK2, JAK3 | MAOB 4094/4885BCHE 4788/4885CYP4F2 1421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.